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Abstract
Following the recent successes of malaria control in sub-Saharan Africa, the gametocytocidal drug primaquine
needs evaluation as a tool to further reduce the transmission of Plasmodium falciparum malaria. The drug has
scarcely been used in Africa because of concerns about its safety in people with glucose-6-phosphate
dehydrogenase (G6PD) deficiency. The evidence base for the use of primaquine as a transmission blocker is limited
by a lack of comparable clinical and parasitological endpoints between trials. In March 2012, a group of experts met
in London to discuss the existing evidence on the ability of primaquine to block malaria transmission, to define the
roadblocks to the use of primaquine in Africa and to develop a roadmap to enable its rapid, safe and effective
deployment. The output of this meeting is a strategic plan to optimize trial design to reach desired goals efficiently.
The roadmap includes suggestions for a series of phase 1, 2, 3 and 4 studies to address specific hurdles to
primaquine’s deployment. These include ex-vivo studies on efficacy, primaquine pharmacokinetics and
pharmacodynamics and dose escalation studies for safety in high-risk groups. Phase 3 community trials are
proposed, along with Phase 4 studies to evaluate safety, particularly in pregnancy, through pharmacovigilance in
areas where primaquine is already deployed. In parallel, efforts need to be made to address issues in drug supply
and regulation, to map G6PD deficiency and to support the evaluation of alternative gametocytocidal compounds.
Keywords: Plasmodium falciparum, Malaria, Primaquine, 8-aminoquinoline, Transmission, Gametocyte, Glucose-6-
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Background
Current World Health Organization (WHO) guidelines
recommend the “addition of a single dose of primaquine
(PQ) (0.75 mg/kg) to artemisinin-based combination
therapy (ACT) for uncomplicated falciparum malaria as
an anti-gametocyte medicine, particularly as a component
of a pre-elimination or an elimination programme” [1].
However, unlike recommendations for other anti-malarial
treatments this does not come with the supporting state-
ment “Strong recommendation, high quality evidence”.
This is because there are limited data to suggest that
primaquine is safe and efficacious for this use, especially
to support regulation and licensure. This is striking given
that primaquine has been in the anti-malarial drug
arsenal since the 1950s and historical studies strongly
suggest that primaquine is highly effective at blocking
transmission. Worldwide, 20 countries include prima-
quine as first-line treatment for Plasmodium falciparum
in their national policy. None of these countries are in
Africa [2].
There are an increasing number of reports of declining
transmission intensity in many parts of sub-Saharan
Africa, bringing malaria transmission to pre-elimination
levels in some countries. There is also increasing recog-
nition that additional strategies aimed specifically at the
transmission stages of P. falciparum are required both to
further reduce transmission and to sustain the gains
made by current control efforts. The previously high
levels of malaria transmission may be one of the main
reasons why primaquine has not been used widely in
Africa, with only very frequent delivery of the drug being
likely to have any impact on transmission [3]. However,
the most likely reasons for the limited use of primaquine
in Africa are concerns over safety, given the conservation
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of the glucose-6-phosphate dehydrogenase (G6PD) defi-
ciency polymorphism in the population.
Using an anti-malarial drug with the goal of inter-
rupting malaria transmission rather than clinical cure
necessitates a clearly-defined assessment of safety and
efficacy with benefits at the individual level and at the
community level being considered. For primaquine, the
optimal dose to achieve such endpoints remains undeter-
mined. The recommended 0.75 mg/kg dose is associated
with significant haemolysis in some susceptible indivi-
duals [4-6], but this dose may well be excessive for the
transmission-blocking activity [7]. For the purpose of
comparison, doses in this report that are expressed as a
milligram per kilogram (mg/kg) equivalent assume an
average adult weight of 60 kilograms.
The limited safety data available on single dose
primaquine has lead to the requirement of prior testing
for G6PD deficiency and pregnancy to avert risk. The
necessity for this additional testing has a significant
impact on the feasibility, cost effectiveness and the achiev-
able population coverage of large scale primaquine-based
interventions. More information on the consequences of
single-dose primaquine administration on individuals/
populations with a relevant range of G6PD enzyme ac-
tivity levels is required urgently if 8-aminoquinolines are
to be deployed to interrupt transmission.
Meeting objectives
With these issues in mind, a meeting of experts was
convened to review and discuss existing data on the use
of primaquine in Africa for transmission-blocking and
to examine the road-blocks that could be overcome to
enable and inform its safe use.
Specific objectives of the meeting were to:
1. Identify key road-blocks to deployment of short
course primaquine or similar drugs in Africa to
reduce transmission of falciparum malaria.
2. Reach consensus on study endpoints so as to
maximize comparability between transmission
prevention studies.
3. Generate a list of deliverables that will move forward
deployment of primaquine in Africa.
Meeting sessions
Country program perspectives and potential use for
primaquine
Chris Drakeley and Roly Gosling introduced the meeting
by providing the current context for the use of prima-
quine and highlighting the fact that the reductions in
malaria transmission that have been described in many
sub-Saharan African settings may well be linked to in-
creasing spatial, temporal and even demographic hetero-
geneity in infections. Spatial targeting of control efforts
is likely to make interventions, such as mass drug
administration (MDA) more feasible [8]. National malaria
control programmes that have seen success in malaria
control in the last decade are looking to implement new
tools to sustain existing reductions and to further reduce
transmission. The question is whether primaquine is
one of these tools?
Salhiya Ali described current malaria transmission
in Zanzibar, which is characterized by perennial and
declining transmission. The sporozoite rate decreased
from 4.3 in 2005 to 0% in 2009 and the most recent para-
site prevalence was 0.067%. Recent Zanzibar Malaria
Control Programme reports suggest that transmission
has become highly heterogenous with cases restricted to
relatively few weeks per year and to a few localities.
Primaquine is not used, but its use could be considered
to facilitate further reductions by targeting hot spots,
or in treating confirmed clinical cases. The local distri-
bution of gametocytaemia and G6PD deficiency is not
known.
In Ethiopia, both P. falciparum and Plasmodium vivax
are endemic and Ashenafi Assefa indicated that the mal-
aria strategy for 2011–2015 includes a plan for elimination
by 2020. Primaquine was used in Ethiopia for 25 years up
until 1990. Chloroquine (CQ) plus primaquine was first-
line treatment for both species. There is no documenta-
tion of adverse effects due to primaquine in this period.
When sulphadoxine-pyrimethamine (SP) was introduced,
it was considered not feasible to administer three drugs,
therefore, primaquine was dropped. At present, prima-
quine is used for radical cure of P. vivax, but not for
P. falciparum. The barriers to using primaquine in
Ethiopia include: 1) a lack of documentation of the distri-
bution and clustering of G6PD deficiency (small studies
suggest that prevalence is between 1.4 and 6.7% among
some minority groups) [9], and 2) uncertainty about the
efficacy of primaquine for interrupting transmission of
P. falciparum in Ethiopia.
Karen Barnes gave a historical perspective of malaria
control in South Africa. Previously, the country had high
levels of malaria transmission. In 1938, there were 22,000
deaths due to malaria in Kwazulu-Natal. Subsequently,
an aggressive approach to malaria control including
mapping, malaria surveys, and vector control has reduced
the burden considerably but case incidence has remained
at a steady state since 2001. The Ministry of Health has
now set a goal for elimination by 2018. The biggest chal-
lenges include imported malaria, and the perception that
malaria is not a public health problem, leading to central
budget cuts. Given the already aggressive measures in
place, the addition of a transmission-blocking drug such
as primaquine could be required to achieve elimination.
One challenge is that primaquine is only available on an
individual patient basis for radical cure of P. vivax. In
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South Africa, the very high rate of tuberculosis and HIV
infection means that the potential for drug interactions
with other anti-infective therapies must be considered if
primaquine is to be used at a population level. The risk
of primaquine-associated haemolysis in people living
with HIV infection may differ from that in uninfected
people.
In contrast to the aforementioned countries, Diadier
Diallo reported that malaria transmission in Burkina
Faso is still high. The use of a combination of inter-
ventions, such as long-lasting insecticidal nets (LLINs),
indoor residual spraying (IRS), and effective artemisinin
combination therapy (ACT) with a long half-life part-
ner drug such as dihydroartemisinin-piperaquine is a
proposed strategy. Co-administration of ACT with prima-
quine (or alternatives such as methylene blue) for con-
firmed malaria episodes and mass drug administration
(MDA) may help to further reduce transmission. This
strategy may be particularly appropriate in the Sahel area
where transmission is highly seasonal and relatively low,
making it a potential target for elimination activities.
Challenges include the high mobility of human and vec-
tor populations particularly from Mali and Niger.
Historical studies on single dose or short course
primaquine for blocking transmission of P. falciparum
Chi Eziefula highlighted that the current recommenda-
tions for primaquine are based on studies with very small
numbers of participants. The parent 8-aminoquinoline,
pamaquine (or plasmoquine), developed in the 1920s, was
shown to have activity against P. vivax and Plasmodium
ovale relapses, and against both sporozoites and gameto-
cytes of all species [10,11]. A derivative of pamaquine,
primaquine was developed in the 1940s by the United
States army to prevent relapse of P. vivax in soldiers
returning from Korea and to prevent the import of malaria
into the country [12].
In 1973, the WHO recommended a single dose of
primaquine (0.75 mg/kg ) for malaria transmission-
blocking and considered prior screening for G6PD defi-
ciency unnecessary [13]. It was not until 2010 that the
WHO Malaria Treatment Guidelines (Second Edition)
changed to indicate that the risks of haemolysis in G6PD
deficient patients should be given consideration prior to
primaquine-based interventions.
The currently recommended single dose of primaquine
is based on limited efficacy data. In 1961, in Liberia,
Burgess and Bray found that a single dose of 0.75-
1.5 mg/kg primaquine administered to12 children cleared
circulating gametocytes by day 9 [7]. In 1961, also in
Liberia, Gunders administered 0.45-1.1 mg/kg of prima-
quine in combination with pyrimethamine to 22 children
and adults. Gametocytes were cleared after a mean of
5 days post treatment, and no mosquito infections
occurred in feeding assays [14]. Primaquine was paired
with amodiaquine (AQ) in a large scale MDA conducted
by Clyde in 1962 in a hyperendemic area of Tanzania.
More than 15,000 subjects were studied in three clusters:
weekly administration, fortnightly administration, and
monthly administration. Outcome measures included
asexual parasite, gametocyte and sporozoite rates. After
six months there was a ten-fold reduction in parasite
prevalence with weekly and fortnightly administration
but not with monthly administration [3]. Except for the
work by Clyde, there are no substantial field data that
indicate that single dose primaquine decreases trans-
mission of P. falciparum.
Safety data for primaquine use in Africa or African
Americans are equally limited despite the fact that they
inform contemporary guidelines. Burgess and Bray com-
ment that primaquine was “well-tolerated”[7]. Clyde
reported no safety data and it is unclear who was
excluded from treatment [3]. In a series of studies in
G6PD deficient African-American volunteers, Alving and
colleagues showed that, in three individuals, haemolysis
occurred with daily administration of 30mg (approxi-
mately 0.5 mg/kg) of primaquine. But, after three weeks,
the haematocrit recovered and lower doses resulted in
less haemolysis. Eight weekly doses of 60 mg and 45 mg
were not associated with haemolysis [15,16]. Daily
administration of 30mg of primaquine to African
Americans resulted in significant haemolysis in 1%, com-
pared to no severe haemolysis when 15 mg was adminis-
tered [17]. Tolerance in a pregnant woman (28 weeks
gestation) has only been reported by Burgess and Bray,
but there was no documentation of birth outcomes [7].
In a more recent study, Kenyan school children were
randomized to receive 15mg primaquine daily or three
times a week as a malaria prophylactic. It is not clear
whether G6PD deficient individuals were included and
haemoglobin levels are not reported but again the
authors note simply that “primaquine was remarkably
well tolerated in our studies” [18].
Kevin Baird remarked that any discussion about
primaquine efficacy is necessarily also a discussion about
toxicity as there are inherent risks of the drug in situa-
tions when the individual patient may not benefit. He
highlighted the importance of employing the ethical
principles of autonomy, justice and beneficence to game-
tocytocidal therapy [19]. The 45 mg dose of primaquine
is based on data obtained in very few, healthy indivi-
duals. This dose was proposed in an era where the goal
of the US military was not to find the lowest efficacious
dose, but rather to show that the drug worked. The first
dose-finding study by Alving in 1960 included one single
patient [16]. It was subsequently observed that daily but
not weekly administration of 0.25 mg/lb of body weight
(~0.55 mg/kg) to G6PD deficient-children resulted in
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haemolysis [20]. Rieckmann and Burgess both showed
declines in gametocytes, oocysts and sporozoites follow-
ing a dose of 45 mg of primaquine but a similar efficacy
was seen with lower doses of 30 mg and 15 mg [7,21,22].
Importantly, these evaluations were conducted without
co-administration of a blood schizontocidal drug.
In 1944, the US government abandoned pamaquine as
a means of preventing relapses of P. vivax due to its
haemolytic toxicity and drug interactions. Primaquine
was introduced as a gametocytocidal agent at the 45mg
dose based on Alving’s work, a dose which was readily
available and in use for chemoprophylaxis in American
soldiers in Southeast Asia at the time. Some significant
haemolysis was seen, mostly in African Americans; there
were no deaths but there were several cases of renal fail-
ure with daily dosing for 14 days[17]. Summarily, the
recommended 45 mg dose may be too dangerous for use
in mass drug administration, especially given the limited
data on transmission reduction with this strategy.
Recent studies on the use of primaquine in Africa
Data from two Tanzanian studies which employed single
dose primaquine were reviewed by Teun Bousema. In the
first study, treatment with sulphadoxine-pyrimethamine
(SP) and artesunate (As) was given to children aged 3 to
15 years with uncomplicated falciparum malaria. They
were randomized to receive placebo or a single dose of
0.75 mg/kg of primaquine on the third day of treatment
(day 2). Compared to the control arm, primaquine ad-
ministration on day 2 decreased the area under the curve
of gametocyte density over time and the duration of
gametocyte carriage. The effect was apparent for two
weeks; using quantitative real time nucleic acid sequence-
based amplification (QT NASBA), 3.9% had gametocytes
on day 14 in the primaquine arm, and the density was
extremely low, compared to a prevalence of 62.7% in
the control arm [23]. Haemoglobin fell in both arms
but the drop was more pronounced in the primaquine
arm. However, this effect was transient and there was
no symptomatic anemia. A haemolytic effect was seen
even in some individuals without genotypic (A- variant)
G6PD deficiency [23].
In a subsequent cluster randomized study, using
MDA in lower Moshi [24], single dose primaquine was
given with SP plus As treatment to 1110 individuals
older than 1 year with primaquine dosages based on
weight (approximately 0.75 mg/kg). It was not possible to
assess post-intervention incidence or prevalence because
P. falciparum transmission had dropped to very low
levels. However, safety outcomes, based on haemolysis,
were available. Moderate haemolysis occurred follow-
ing primaquine treatment in 40% of G6PD deficient
(A- genotype) individuals but in only 4.5% of non-
deficient individuals. There was no clinical compromise
due to anemia in any of the children, except in one child
in the primaquine arm, whose haemoglobin dropped
from 8.3 g/dL to 4.8 g/dL. It was noted that in all cases
haemolysis was transient, recovering by day 14 after
treatment.
As a former colleague of Professor Li Guoqiao, Keith
Arnold represented him and presented data from an
MDA campaign in Moheli Island, Comoros. Dr. Arnold
began by reviewing Professor Li’s work on primaquine in
South East Asia, which served as the basis for the drug
regimen used in Comoros. In the late 1990s, Professor
Li developed CV8 (320 mg piperaquine phosphate,
32 mg dihydroartemisinin, 5 mg primaquine phosphate,
90 mg trimethoprim). An estimated 1.3 million doses of
this drug were administered across Vietnam as part of the
National Malaria Control Programme in 2000. There were
no documented reports of haemolysis. Data were pre-
sented from subsequent dose-finding studies. Artequick
(dihydroartemisinin piperaquine given at 0 and 24 hours)
was administered in clinical cases followed as inpatients
for 30 days followed by administration of 6 mg (7 patients),
7.5 mg (3 patients) or 8 mg (32 patients) of primaquine.
A 7.5 mg dose of primaquine rendered gametocytes non
infectious at 24 hours. Following 8 mg of primaquine,
there were oocysts but no sporozoites in membrane-fed
mosquitoes. He decided on the use of Artequick + 9 mg
primaquine for MDA after performing safety studies
using 8 mg and 10 mg doses in small numbers of indivi-
duals with G6PD deficiency in South East Asia. An MDA
campaign in 2003 in Cambodia using this regimen
resulted in a large reduction in population parasite car-
riage over three years [25].
In Moheli Island, Comoros the baseline P. falciparum
parasite prevalence in children ranged from 10-95% in
25 villages. Given a mosquito life expectancy of 30 days,
the strategy was to give Artequick for three days plus
9 mg of primaquine on day 1 (Round 1) and day 35
(Round 2). Also, beginning on day 21, 9 mg primaquine
alone was given every 10 days, 12 times. Patients less
than six months of age were excluded. Treatment cover-
age for both rounds was reported as >90% and data from
monitoring between 2007 and 2009 suggested a reduc-
tion of parasite prevalence to <5%. The exception was an
area on the south of the island where parasite rates
decreased from 94% to 19% with frequent migration from
a nearby island suggested as the reason for the persist-
ence of parasites. There were no reports of haemolysis,
although it was not measured objectively. The baseline
prevalence of G6PD deficiency was estimated to be 15%.
G6PD deficiency prevalence testing and safety issues
G6PD is an essential erythrocytic enzyme. G6PD defi-
ciency is one of world’s most common genetic poly-
morphisms. Dennis Shanks described the current array
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of diagnostic tests available to test for G6PD deficiency.
Testing of the enzymatic activity of G6PD on freshly-
collected blood samples is the most widely used method.
The NADPH fluorescent spot test is most commonly
used and is currently recommended by the International
Committee for Standardization in Haematology, but it
requires a UV lamp and is difficult to do on high volumes
of samples. Other diagnostic tests include cytochemical
assays, DNA sequence analysis of the G6PD gene, and
some rapid diagnostic test formats not yet validated for
public health application. In theory, testing for G6PD de-
ficiency is not difficult, but most tests have limitations
for large-scale field application, such as expense, require-
ment for electricity, duration of test procedure, and sen-
sitivity of reagents to light and heat, low detection
threshold, and relatively low throughput capacity.
Rosalind Howes described G6PD deficiency as being
widespread in tropical regions of sub-Saharan Africa,
commonly affecting over 15% of the male population,
and in some isolated areas of West and Central Africa
reaching up to 30% of the male population. It is consid-
ered that severe G6PD deficiency is likely to exist in
Africa but its prevalence is unknown. Shanks noted that
country-wide MDA with primaquine has been used in
China and Nicaragua, both areas with a low prevalence
of G6PD deficiency and that in both programmes there
were some cases of severe haemolysis. The three primary
safety/ tolerability issues with primaquine are gastro-
intestinal upset, methaemoglobinaemia, and haemolytic
anemia in those who are G6PD deficient. G6PD enzyme
activity is at best a partial biomarker of clinical effect and
the clinical effect is likely dependent on other factors
including red blood cell count, gender, and other gen-
etic factors.
Testing for G6PD deficiency
Gonzalo Domingo observed that genotyping for G6PD
deficiency is most commonly carried out for known
prevalent mutations at the risk of misclassifying study
participants with unknown G6PD deficiency traits as
normals. Phenotyping, either quantitative or qualitative,
determines G6PD activity in red blood cells and can be
defined as a relative deficiency in activity compared to a
predefined “normal” activity or in absolute terms in
units per gram of haemoglobin. Most studies in Africa
have used a semi-quantitative/qualitative fluorescent
spot test and observed a high degree of discordance be-
tween phenotyping and genotyping not limited to just
heterozygous women. Other phenotypic tests e.g. cyto-
chemistry can identify heterozygous females. Spectro-
photometry is the gold standard and fluorescent spot
tests are useful for screening. The ideal specification for
a G6PD deficiency test is difficult to achieve as there is
no defined acceptable cut-off of G6PD activity. The chal-
lenges are that the measurement of enzyme activity is
extremely sensitive to temperature, specimen volume,
and possibly specimen type. Of the available tests that
run on point-of-care platforms, BinaxNOW is limited
by its operating temperature and Access Bio by its small
sample volume, which may be a source for perform-
ance variability. The BinaxNOW test detects a cut-off
of 30-40% enzyme activity and was designed to detect
hemizygous males. Detecting heterozygous females re-
quire platforms that can detect and enumerate intra-
erythrocytic G6PD activity. The next steps include an
evaluation of currently available tests for G6PD defi-
ciency under ideal laboratory conditions, field evaluation
under controlled conditions, and engaging with the
diagnostic sector to define a value proposition for point-
of-care G6PD deficiency tests. Ongoing efficacy studies
for primaquine represent an opportunity to obtain G6PD
deficiency cut-off levels.
Examples of possible study designs— clinical and
field-based
Lorenz von Seidlein and Teun Bousema considered the
sequence of studies required to establish the role of
primaquine in the response to artemisinin resistance as
well as for the elimination of falciparum malaria. Before
population-level interventions are considered, three main
questions will need to be addressed: 1) What drug con-
centration is needed to inhibit gametocytes, 2) which
primaquine regimen is required to achieve these gameto-
cyte inhibitory concentrations and 3) can this dose be
safely administered to both sexes and all age groups?
Excluding young children and women of reproductive
age from MDA will seriously reduce coverage and is
likely to render any intervention meaningless. Since a
prospective study of giving single dose primaquine dur-
ing pregnancy is not likely to be approved, retrospective
approaches e.g. pharmacovigilance during large field
trials should be explored as a way of gaining informa-
tion about the safety of primaquine in pregnancy.
One option for field evaluation is the cluster rando-
mized trial. A double-blinded community-randomized,
placebo-controlled trial in The Gambia evaluated MDA
with sulphadoxine- pyrimethamine (SP) plus single dose
artesunate (AS1) in 18 villages and achieved 89% coverage
[26]. There was an initial decrease in malaria incidence
but the effect quickly disappeared. Possible reasons for
a failure to reduce transmission intensity might be that
the baseline transmission intensity was too high, that
there was migration of infected individuals or mosqui-
toes, or that the drug regimen was not ideal. A double-
blinded community-randomized, placebo-controlled trial
was conducted in Tanzania in a setting of very low and
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seasonal malaria transmission (entomological inoculation
rate of approximately 2) using MDA with SP on day 1
plus artesunate for 3 days and primaquine on day 3 [27].
Coverage of 93% was achieved, but the study failed to
show a reduction in transmission intensity due to the
small number of outcome events (P. falciparum infections)
in both the intervention and control groups. These studies
raise two important questions: 1) Are sub-microscopic
parasite densities sufficient to sustain transmission and
2) what is the ideal transmission intensity at which to
conduct MDA? It was considered that studies designed
to detect the community benefit of ACT versus ACT plus
primaquine would potentially necessitate very large sample
sizes and alternative strategies to evaluate MDA should
also be considered. The community effect of insecticide-
treated bed nets extends beyond the households that use
nets and has been estimated by measuring the distance
between control and intervention villages and com-
pounds where protection is seen. Such an effect may exist
for primaquine- based interventions such that targeted
coverage has a high impact. Less ambitious trial designs
could encompass treatment of clinical malaria cases,
focal screen–and-treat campaigns, or primaquine could
be incorporated into active case detection activities using
standardized outcome measures such as entomological
parameters, gametocyte prevalence by molecular methods,
parasite prevalence/ molecular force of infection, and
malaria incidence during follow-up.
The design of trials of MDA with primaquine should
help inform a potential strategy for interventions. What
is the threshold endemicity level at which MDA with
primaquine should be considered? How many rounds of
MDA are required and at what interval to give a given
effect? Even if efficacy and safety can be established, the
issue of willingness to participate in MDA must be con-
sidered. In settings of very low transmission and minimal
risk, e.g. Swaziland, the community might not be as
accepting of MDA as compared to a country with higher
endemicity as the perceived benefit is lower.
Potential study endpoints-clinical and field studies
Heiner Grueninger emphasized that study endpoints
should be designed to facilitate both effective treatment
and increased knowledge of the study drug. In the con-
text of using primaquine for a new indication of trans-
mission-blocking, the study design should address the
requirements set by authorities for obtaining regulatory
approval to use the drug. Consequently, endpoints should
be considered with input from both industry and policy
makers in order to expedite drug deployment in endemic
settings.
Chris Drakeley discussed biomedical efficacy end-
points. Abrogation of infection in mosquito infectivity
studies is a compelling functional bioassay yet only one
existing study involving primaquine satisfied Cochrane
review criteria (Graves and Gelband, in press). In this
study, mefloquine and SP plus primaquine stopped
infection over 14 days post treatment [28]. The mosquito
feeding assay methods for assessing post treatment
infectivity of subjects offer different options for evalu-
ation, but are not standardized. Direct skin feeding of
mosquitoes on treated individuals is most representative
of natural infection dynamics but presents logistical and
ethical concerns. Using venous blood allows both direct
membrane feeding but also serum replacement with un-
treated or treated serum to examine the effect of dif-
ferent serum compositions, such as drug metabolites.
Reproducibility of results is an important issue with no
clear guidelines on how to feed mosquitoes, how many
mosquitoes should be fed per assay, because the robust-
ness of the estimate of prevalence of infection depends
on the number fed [29], and on which day post-treatment
participants should be tested for infectivity. For example,
primaquine has a short half-life so infectivity could be
measured after 24 hours, whereas, for the purpose of
MDA, it is probably pertinent to know for how long the
subject has reduced infectivity and testing for infectivity
up to 28 days may be relevant. This latter point could be
addressed by staggering sampling time points between
participants to reduce the number of bleeds per individ-
ual. Further studies may be required to confirm the effect
on infectiousness to wild mosquito populations as natural
infections have been shown to be successful at very low
gametocyte densities suggesting high vector susceptibility
[30]. Such feeding experiments may not be warranted or
practical for larger field evaluations and a surrogate mar-
ker for transmission would be preferable.
Although, there is no standardized, validated marker of
infectiousness of the human host, the most widely used
marker to compare drugs is the prevalence of gameto-
cytes 7 days post treatment [31]. Gametocyte density is
less relevant at low gametocyte counts found in chronic
and asymptomatic infections as the correlation between
infectivity and low gametocyte density is poor. The
measurement of gametocyte prevalence and density
depends on the method of detection with 5- to 10- fold
differences seen with molecular methods compared to
microscopy[32]. Gametocyte densities can be integrated
using area under the curve (AUC) to provide an estimate
of gametocyte carriage [33,34]. In natural infections this
is likely to vary by age with young children with clinical
disease having short, intense gametocytaemia (abrogated
by drugs or gametocyte death) and older semi-immune
individuals, who can have asymptomatic infections for
up to a year [35] and maybe longer, with a more pro-
longed AUC.
The issue of how to tailor the design of studies using
primaquine to include endpoints that are meaningful to
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regulatory authorities was tackled by Justin Green. The
key question is what level of evidence do we require in
order to use primaquine as a transmission-blocking agent?
He referred to ongoing studies using tafenoquine to high-
light how bespoke endpoints are being used to achieve
licensure. Tafenoquine is an 8-aminoquinoline developed
by the US army and the Walter Reed Army Institute of
Research (WRAIR) with GlaxoSmithKline (GSK). It has
a long half-life (14–17 days), which may confer advan-
tages as an anti-parasitic agent, but also risks, given
that the duration of haemolysis in individuals with
G6PD deficiency is also prolonged [36]. The drug is
slowly metabolized and the parent compound is respon-
sible for the anti-malarial effect [37]. Tafenoquine is
being developed as a radical cure of P. vivax infection.
Green described a dose-ranging study in individuals
over 16 years with P. vivax infection evaluating chloro-
quine alone compared with standard dose chloroquine
plus primaquine 15mg (for 14 days) and different single
doses of tafenoquine (50mg, 100mg, 300mg, and 600mg)
given on day 1 or day 2 (NCT01376167). The primary
endpoint is relapse at 6 months with secondary end-
points of relapse at 4 months, time to relapse, parasite
clearance time, fever clearance time, gametocyte clear-
ance time (by microscopy), safety and pharmacokinetics/
pharmacodynamics.
These pivotal endpoints are designed with regulatory
requirements in mind so that wording related to end-
points can be incorporated into a label claim. From the
perspective of industry, this can determine the potential
volume of sales (the percentage of the primaquine
market obtainable). For trials with primaquine, or other
transmission-blocking candidates, it is necessary to
decide how important it is that the study endpoint is on
the label and whether stakeholders demand a “label
claim” or an indication for approval. For transmission
markers to stand as endpoints for a regulatory level
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Figure 1 Preliminary modeling of administration of primaquine together with ACTs in a range of transmission settings. A simulation of
adding primaquine to ACT first line treatment versus ACTs only in a seasonal setting. In this simulation 80% of clinical cases are treated with ACT
alone or ACT-PQ. Primaquine is assumed to reduce the duration of infection by 78% and the level of infectiousness by 67% in treated patients
compared to those treated with ACT alone. In a low transmission scenario, adding PQ to the treatment of clinical cases causes a higher relative
reduction than in higher transmission scenarios. Ro differs between settings. Migration is not allowed for. With the kind permission of Lucy Okell,
Jamie Griffin & Azra Ghani. For further details, see reference [40].
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molecular method such as detection of pfs25 with QT
NASBA [38] or microscopic gametocytaemia, correlates
with transmission.
Typically, the pharmaceutical industry focuses on the
risk-benefit of a particular drug in the individual. For
primaquine, the drug may be of more benefit to some-
one other than the recipient, raising the ethical question
of whether it is acceptable to give a drug for community
benefit. This issue is also pertinent to transmission-
blocking vaccines [39]. Justin Green considered that it is
crucial that primaquine trials include individuals with
G6PD deficiency (including heterozygote females) and
describe the risk of haemolysis in these patients. There
is no consensus on whether there is any acceptable
degree of haemolysis following a drug intervention for
malaria in clinical cases or in asymptomatic individuals.
Modeling the potential use of primaquine
Teun Bousema discussed how to extrapolate the effect
of primaquine in the individual to community-level
transmission, acknowledging that the infectious reservoir
of malaria may vary with transmission setting. A recent
model by Lucy Okell and colleagues [33] suggests that
infectiousness post ACT alone is 13 days and post ACT
plus primaquine is 3 days. Using this model that incorpo-
rates population age structure, immunity, heterogeneous
exposure and as well multiple interventions as covariates,
the addition of primaquine to ACT as first-line treatment
significantly reduces transmission in low endemic set-
tings but not in higher transmission settings (Figure 1).
The proportion of people who received primaquine in
addition to ACT is a key parameter suggesting prima-
quine needs to be given with all courses of ACT to have
an effect. The models were further extended to investi-
gate the effect of primaquine as part of an MDA [40] in a
non-seasonal setting with 9% prevalence of P. falciparum.
Giving MDA every four months caused an 80% reduction
in transmission, but not elimination. With MDA every
six weeks one could plausibly reach elimination. Prelim-
inary models suggest that MDA may be more successful
in areas of seasonal transmission (Figure 2). The dur-
ation of drug action is important and a long acting
ACT plus a long acting 8-aminoquinoline could be an
optimal combination.
An approach targeting malaria transmission hotspots
may be appropriate for all endemic settings [8]. The
hypothesis is that hot spots catalyse transmission and
targeting them would reduce transmission both within
and outside the hotspot. Modeling hotspot interventions
with no drug treatment but with insecticide-treated bed
nets scaled up to 80% coverage and targeted IRS had a
significant effect on transmission. The effect of adding
primaquine should be investigated. Models of transmis-
sion assume a long time-course and there was discussion
as to the stability of hot spots and how this would affect
the efficacy of an intervention.
Meeting outputs
Possible approaches for the use of primaquine to
interrupt malaria transmission
Having reviewed the existing data, the second aim of the
meeting was to identify the roadblocks to deployment of
primaquine in Africa (Figure 3), decide on common
study endpoints and to determine the next steps. As a
starting point the group determined the intended indica-
tions of primaquine (Figure 4), a target product profile
(Figure 5) and common endpoints for infectivity, efficacy
and safety studies (Figure 6).
Key roadblocks to the deployment of primaquine
Safety and efficacy of primaquine
The paucity of evidence for primaquine’s safety and
efficacy for transmission-blocking were seen as major
issues, particularly, the lack of data supporting the safest
and most efficacious dose. If primaquine is going to be
used to maximal benefit then it must be safe to deploy in
G6PD deficient individuals and women of childbearing
age and it must be safe to co-administer with HIV and
tuberculosis treatments without adverse drug interactions.
Most crucially, evidence is lacking for any transmission-
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Year since PQ introduction
ACT-PQ ACT only
ACT-PQ + MDA
Figure 2 The effect of annual MDA with primaquine in addition
to primaquine and ACT treatment of clinical cases in a low
transmission setting. In a seasonal, low transmission setting, giving
ACT+ primaquine to clinical cases plus an annual MDA with ACT
plus primaquine could reduce malaria levels close to elimination if
repeated for a number of years; however the model does not
allow for immigration of malaria cases. With the kind permission
of Lucy Okell, Jamie Griffin & Azra Ghani. For further details,
see reference [40].
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primaquine to routine anti-malarial treatment of symp-
tomatic individuals.
Suitable endemicity for use of primaquine
It was agreed that use of primaquine is most likely to
have an impact on transmission intensity in areas char-
acterized by low endemicity prior to the intervention, i.e.
P. falciparum parasite rate (PfPR) by microscopy of less
than 5%, or an EIR (entomological inoculation rate) less
than 1. In such settings, there is a low frequency of
symptomatic parasitaemia so the greatest benefit is likely
to result from treating asymptomatic infections as well,
through MDA or screen-and-treat initiatives. The optimal
strategy for delivering primaquine-based MDA in terms
of who to treat, at what threshold endemicity, with what
regimen and how often is unknown.
Mathematical modelling indicates a limited effect at
higher transmission intensities (PfPR> 10%). However,
Figure 3 Summary of key discussion points—roadblocks to the deployment of primaquine.
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further iterations are needed to assess the additional
effect of primaquine interventions together with other
control tools at a range of transmission intensities. As
was the situation in Aneityum, Vanuatu [41], there may
be other higher transmission settings where interruption
of transmission could occur using MDA with primaquine
because of limited human migration.
Partner drug for primaquine
For community campaigns with primaquine, the partner
ACT should probably differ from the recommended first-
line anti-malarial treatment. An alternative ACT may be
required for community-wide MDA or in circumstances
where repeated rounds of MDA are envisaged. However,
in smaller hotspots of high transmission intensity where
fewer rounds of treatment with ACT-primaquine are
needed, the standard first-line ACT could be considered
as the partner to primaquine. The relative gametocytocidal
activity of the partner ACT, its half-life for killing asexual
parasites and the potential for drug interactions or for
synergy with primaquine will need to be considered.
Drug supply and regulation
The manufacture and supply of the appropriate dose
and formulation of primaquine was seen as a major
obstacle for primaquine deployment. Currently, there
are primaquine shortages globally and in Africa, the
procurement of supplies to treat P. vivax where it is
endemic is a challenge.
Further information on the current challenges for the
manufacture and supply of single- or low-dose prima-
quine is required. A review of the current situation of
primaquine manufacture and supply should be carried
out with the aim of identifying the steps needed to ensure
an adequate supply of primaquine formulated in the
correct dose should low dose primaquine be found to
be efficacious. It is likely that primaquine for the clear-
ance of P. falciparum gametocytes will remain off label.
In order to ensure the smooth process from manufacture
to implementation, it was recommended that stake-
holders from industry and governments, including regu-
latory authorities be brought together to discuss these
challenges.
Figure 4 Endpoints for standardisation and regulatory compliance.
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Alternatives to primaquine
The meeting agreed that seeking alternative gametocytoci-
dal drugs to primaquine was paramount due to the safety
concerns with 8-aminoquinolines. The 8-aminoquinoline
tafenoquine appears to have a similar safety profile to
primaquine (haemolysis in people with G6PD deficiency),
but being long-acting, may potentially inhibit gametocyte
infectivity for longer. Should a safe, low dose be found,
tafenoquine could be a useful tool in the elimination
of P. falciparum. There is increasing evidence for methy-
lene blue having a better safety profile [42,43], but more
work needs to be done on regimen, dose-finding and
acceptability [44,45]. The group supported the further
development of these drugs and considers it a priority to
develop more compounds active against transmission
stages for all species of malaria.
The roadmap
Three themes were identified that need to be addressed
simultaneously. Firstly, there are evidence gaps for
primaquine itself, secondly, the manufacture and supply
of primaquine needs mapping and thirdly, efforts to
search for a safe and effective alternative to primaquine
need to be supported. A schematic of the roadmap is
shown in Figure 7.
Providing evidence of the efficacy and safety of
primaquine
A range of studies from phase 1–4 were proposed that
would inform decisions on the efficacy and safety of
primaquine. These are outlined below.
Phase 1: Identification of the lowest dose for efficacy
Ex vivo gametocytocidal/ infectivity assays: because the
active metabolites of primaquine are currently unknown,
the interpretation of in vitro assays with primaquine is
complicated. A possible approach would be to use healthy
volunteers treated with different doses of primaquine.
The plasma (containing primaquine metabolites) of these
individuals could be used in membrane feeding experi-
ments with cultured parasites to demonstrate lack of
infectivity in mosquitoes of different doses of primaquine
and in combination with ACT.
There is no proven relationship between mosquito
infectivity and gametocytocidal effects so this may need
to be repeated with a variety of parasite lines and volun-
teers of different ethnic backgrounds.
It was noted that much needed pharmacokinetic
studies could be performed during the same experiments
as could studies evaluating the different partner ACT,
other gametocytocidal drugs and drugs in common use
Figure 5 A Target Product Profile for primaquine.
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that may interact with primaquine (e.g. antiretrovirals
and drugs for tuberculosis).
Phase 2: Establish the safety and efficacy of the optimal
dose of primaquine in relevant sub-groups
 Efficacy of low dose primaquine to assess post-
treatment infectivity using common endpoints (see
below) in G6PD normal individuals. A dose-finding
study is currently under way in Uganda
(NCT01365598).
 Studies to confirm safety of low dose primaquine in
G6PD deficient.
– hemizygous males with lowest doses (dose
escalation studies)
– heterozygous females (dose escalation studies)
– individuals of a given phenotypic G6PD
enzyme function level, to establish a
relationship between G6PD enzyme function
level and safety, a proposed threshold enzyme
function being in the range 20-30%.
 Confirm safety and efficacy in infected population of
unselected G6PD status (timeline 3–4 years).
 If safety with G6PD deficiency remains a problem,
field usable and reliable point of care tests to detect
G6PD deficiency will be needed and the effect of not
treating a proportion of the population on
transmission reduction modeled.
 Programmes to map the geographical distribution of
G6PD deficiency in countries targeted for primaquine
deployment. This should include assessment of the
range of enzyme function levels in the population.
Figure 6 Intended indications for the use of primaquine to interrupt malaria transmission.
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Phase 3: Studies to establish utility at community level
These may measure transmission reduction but may not
necessarily need to be in the form of randomized con-
trolled trials. Much can be learnt from the transmission-
blocking vaccine field where designs such as a ‘stepped
wedge’ design may be used with a focus on the indirect
and community effects. Both prospective and retrospect-
ive pharmacovigilance studies will be needed and preg-
nancy registers will be an important component.
Phase 4: Studies to review the safety in pregnancy
Currently there is no evidence on safety of primaquine
in pregnancy. Post-marketing surveillance is possible as
several countries have adopted primaquine as policy,
such as India, China and Sri Lanka. In these countries,
pharmacovigilance could be supported to do a retro-
spective study following up women of reproductive age
who have been treated with any dose of primaquine.
Conclusion
Primaquine may be a useful malaria control tool in low-
endemic settings in Africa when used in combination
with a blood schizontocide. For maximal effect it will
need to be given to asymptomatic parasite carriers and
therefore a safe and efficacious dose needs to be found
that can be used in populations with G6PD deficiency.
Studies designed to find this dose should contain com-
mon endpoints including infectiousness to mosquitoes
seven days after treatment and gametocyte prevalence
pre-treatment and seven days post-treatment to allow
Figure 7 A projected roadmap for primaquine studies.
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maximal comparability between trials. Safety endpoints
need to be defined, particularly with regard to G6PD
pheno- and genotype and pregnancy. Methylene blue
and tafenoquine are alternative drugs but need further
testing and establishing standard protocols could facili-
tate this process. Community trials should identify the
added benefit of using primaquine in addition to a long-
acting ACT with the endpoint of community transmis-
sion reduction.
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